Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (301-310 of 597) with videos related to

Pageof 60
Sort By:
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Blood|July 22, 2006
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)Elise Chapiro, Eric Delabesse, Vahid Asnafi, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
British Journal of Haematology|July 20, 2018
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analysesCalogero Vetro, Torsten Haferlach, Sabine Jeromin, et al.
Genes, Chromosomes & Cancer|December 2, 2005
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemiasSusanne Schnittger, Tobias M Kohl, Nina Leopold, et al.
Haematologica|December 21, 2014
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSabine Jeromin, Torsten Haferlach, Sandra Weissmann, et al.
Leukemia|August 12, 2023
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICCSandra Huber, Constance Baer, Stephan Hutter, et al.
Haematologica|March 18, 2024
Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesisArmin P Piehler, Marietta Truger, Jan-Hendrik Kozik, et al.
Blood|August 22, 2025
Artificial Intelligence in HematologyAziz Nazha, Olivier Elemento, Sanjay Ahuja, et al.
Leukemia|May 10, 2024
Genomic landscape of CCUS compared to MDS and its implications on risk predictionSandra Huber, Constance Baer, Stephan Hutter, et al.
Pageof 60

Showing results (301-310 of 597) with videos related to

Sort By:
Pageof 60
The Journal of Molecular Diagnostics : JMD|May 18, 2013
Robustness of amplicon deep sequencing underlines its utility in clinical applicationsVera Grossmann, Andreas Roller, Hans-Ulrich Klein, et al.
Blood|July 22, 2006
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17)Elise Chapiro, Eric Delabesse, Vahid Asnafi, et al.
Blood|March 24, 2012
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entityUlrike Bacher, Susanne Schnittger, Katja Macijewski, et al.
British Journal of Haematology|July 20, 2018
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analysesCalogero Vetro, Torsten Haferlach, Sabine Jeromin, et al.
Genes, Chromosomes & Cancer|December 2, 2005
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemiasSusanne Schnittger, Tobias M Kohl, Nina Leopold, et al.
Haematologica|December 21, 2014
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSabine Jeromin, Torsten Haferlach, Sandra Weissmann, et al.
Leukemia|August 12, 2023
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICCSandra Huber, Constance Baer, Stephan Hutter, et al.
Haematologica|March 18, 2024
Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesisArmin P Piehler, Marietta Truger, Jan-Hendrik Kozik, et al.
Blood|August 22, 2025
Artificial Intelligence in HematologyAziz Nazha, Olivier Elemento, Sanjay Ahuja, et al.
Leukemia|May 10, 2024
Genomic landscape of CCUS compared to MDS and its implications on risk predictionSandra Huber, Constance Baer, Stephan Hutter, et al.
Pageof 60